Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-03

Study Completion Date

2023-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

NCT05109442

Advanced Solid Tumor

TERMINATED PHASE1/PHASE2

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NCT05948813

NSCLC EGFR Activating Mutation Brain Metastases

RECRUITING PHASE2

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

NCT04650490

Brain Metastases Non Small Cell Lung Cancer

WITHDRAWN PHASE2

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058

Lung Adenocarcinoma EGFR Positive Non-small Cell Lung Cancer

UNKNOWN PHASE2

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038

Non-Small Cell Lung Carcinoma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted in two phases. The Phase 1/dose escalation phase will gather preliminary safety and tolerability data for escalating doses of AFM24 in combination with SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to be used in the Phase 2a/expansion.

The Phase 2a/expansion portion of the study will gather additional safety, tolerability, efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in subjects with three types of advanced or metastatic EGFR-expressing cancers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Squamous Cell Carcinoma of Head and Neck Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Advanced Solid Tumor Refractory Tumor Metastatic Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Subjects will be enrolled sequentially in cohorts of 3 to 6 subjects into Phase 1/dose escalation. The dose escalation will follow the standard oncology Phase 1 3 + 3 dose escalation design. A minimum of 3 cohorts will be utilized and dose increases will be determined by the Safety Review Committee.

Once RP2D is determined in Phase 1/dose escalation, the Phase 2a/expansion phase will begin enrolling up to 121 subjects.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1, Dose Escalation

It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.

SNK01 (fixed dose) will be administered weekly by IV infusion.

Group Type EXPERIMENTAL

AFM24

Intervention Type DRUG

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

SNK01

Intervention Type BIOLOGICAL

Patient-specific ex-vivo expanded autologous natural killer cells.

Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)

SNK01 (fixed dose) will be administered weekly by IV infusion.

Group Type EXPERIMENTAL

AFM24

Intervention Type DRUG

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

SNK01

Intervention Type BIOLOGICAL

Patient-specific ex-vivo expanded autologous natural killer cells.

Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)

SNK01 (fixed dose) will be administered weekly by IV infusion.

Group Type EXPERIMENTAL

AFM24

Intervention Type DRUG

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

SNK01

Intervention Type BIOLOGICAL

Patient-specific ex-vivo expanded autologous natural killer cells.

Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)

SNK01 (fixed dose) will be administered weekly by IV infusion.

Group Type EXPERIMENTAL

AFM24

Intervention Type DRUG

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

SNK01

Intervention Type BIOLOGICAL

Patient-specific ex-vivo expanded autologous natural killer cells.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AFM24

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

Intervention Type DRUG

SNK01

Patient-specific ex-vivo expanded autologous natural killer cells.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Capable of giving signed informed consent
2. Males and females age ≥ 18 years
3. Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic EGFR-positive malignancy for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator.
4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).
5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below:

1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received ≥ 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody.
2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/PD-L1 antibody.
3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody.
6. One or more measurable tumors lesions per RECIST v1.1
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
8. Adequate bone marrow, hepatic and renal function.

Exclusion Criteria

1. Superior vena cava syndrome contra-indicating hydration
2. Untreated or symptomatic central nervous system (CNS) metastases
3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade ≤ 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia)
4. Treatment with systemic anticancer therapy or an investigational device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment.
5. Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade \> 1) toxicity from previous radiotherapy
6. Clinically significant cardiovascular disease
7. Major surgery within 4 weeks prior to any study treatment administration
8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment.
10. Known history of testing positive for human immunodeficiency virus (HIV), and/or positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.
11. Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring systemic immunosuppressive therapy
12. A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
13. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No